Covaxin effective against double mutant strain found in India, shows 78 pc efficacy against mild to severe COVID-19
New Delhi | Jagran News Desk: India's indigenous vaccine against COVID-19, Covaxin has shown the efficacy of 78 per cent against mild, moderate and severe COVID-19 cases during phase 3 interim analysis of the results. Bharat Biotech, while announcing the phase 3 trials results of Covaxin also noted that the second interim data of the Phase III study also showed that chances of hospitalisation due to the infectious disease were reduced by 100 per cent after taking the Covaxin jab.
Due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78 per cent against mild, moderate, and severe COVID-19 disease, Bharat Biotech said in a statement, adding that the efficacy against asymptomatic COVID-19 infection was 70 per cent, suggesting decreased transmission in Covaxin recipients.
The efficacy data against severe COVID-19 and asymptomatic infections is highly significant, as this helps reduce hospitalisations and disease transmission, respectively, the company said. The Phase III study for Covaxin enrolled 25,800 participants between 18-98 years of age, including 10 per cent over the age of 60, with analysis conducted 14 days post the second dose.
Meanwhile, the Indian Council of Medical Research today also said that the Covaxin neutralises multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well which is being reported in many parts of the country. "ICMR study shows Covaxin neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well," the ICMR tweeted.
ICMR-National Institute of Virology has successfully isolated and cultured multiple variants of concern of SARS-CoV-2 virus: B.1.1.7 (the UK variant), B.1.1.28 (Brazil variant ) and B.1.351 (South Africa variant). ICMR-NIV has demonstrated the neutralisation potential of Covaxin against the UK variant and Brazil variant, the apex health research body said.
ICMR-NIV recently has been successful in isolating and culturing the double mutant strain B.1.617 SARS-CoV-2 identified in certain regions of India and several other countries, the ICMR stated.
(With Agencies Inputs)
Posted By: Talibuddin Khan